The administration of MA242 (dual inhibitor of MDM2 and NFAT1) in combination with gemcitabine inhibits pancreatic tumor growth and metastasis, providing a promising strategy for the treatment of pancreatic cancer [29]. Here, NFATC2 is linked to pancreatic neoplasm.